Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cancer Drug Targets
  4. Fast Track Articles
  5. Fast Track Article
image of Clinical Efficacy and Safety of Anlotinib Combined with Immune 
Checkpoint Inhibitors in the Treatment of Advanced Squamous Cell Lung Cancer: A Retrospective Single-Center Study in China

Abstract

Background

There is a relative lack of real-world data regarding the treatment of advanced squamous cell lung cancer (SqCLC) with anlotinib.

Aims and Objective

This study aimed to investigate the clinical efficacy and safety of combining anlotinib with ICIs for the treatment of advanced SqCLC.

Methods

Sixty patients with advanced SqCLC from December, 2017 to December, 2022, were retrospectively recruited in the final analysis. The overall survival (OS), adverse events (AEs), and short-term clinical effectiveness, including complete remission (CR), partial remission (PR), stable disease (SD), and progression disease (PD) of the study populations, were observed. Objective response rate (ORR) was defined as the combined percentage of CR and PR in all patients. Disease control rate (DCR) was defined as the combined percentage of CR, PR, and SD in all patients. Subgroups were classified based on age (<65 or ≥65), sex (female or male), and the eastern cooperative oncology group (ECOG) score (0-1 or 1-2).

Results

The median age of the study population was 65 years, and 41 (68.3%) of the participants were male. ORR was 21.67%, and DCR was 83.33%. The median PFS and OS were 7.5 and 19.5 months, respectively. Furthermore, the Kaplan-Meier curves demonstrated no significant difference (P >0.05) in PFS and OS between different age groups, sex, and ECOG scores. Bone marrow suppression was the most common AE, followed by immune pneumonia.

Conclusion

The findings of this study confirmed the effectiveness and safety of anlotinib and ICIs for advanced SqCLC.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096299425240925073611
2024-11-06
2025-01-29

  • From This Site

    /content/journals/ccdt/10.2174/0115680096299425240925073611
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  2. Lau S.C.M. Pan Y. Velcheti V. Wong K.K. Squamous cell lung cancer: Current landscape and future therapeutic options. Cancer Cell 2022 40 11 1279 1293 10.1016/j.ccell.2022.09.018 36270277
    [Google Scholar]
  3. Socinski M.A. Obasaju C. Gandara D. Hirsch F.R. Bonomi P. Bunn P. Kim E.S. Langer C.J. Natale R.B. Novello S. Paz-Ares L. Pérol M. Reck M. Ramalingam S.S. Reynolds C.H. Spigel D.R. Stinchcombe T.E. Wakelee H. Mayo C. Thatcher N. Clinicopathologic features of advanced squamous NSCLC. J. Thorac. Oncol. 2016 11 9 1411 1422 10.1016/j.jtho.2016.05.024 27296106
    [Google Scholar]
  4. Shen X.H. Chang Y.Y. Pham R.Q. Chen W.A. Li F.Y. Huang W.C. Lin Y.W. Secular-trend analysis of the incidence rate of lung squamous cell carcinoma in Taiwan. Int. J. Environ. Res. Public Health 2023 20 2 1614 10.3390/ijerph20021614 36674370
    [Google Scholar]
  5. Wilson D.O. Ryan A. Fuhrman C. Schuchert M. Shapiro S. Siegfried J.M. Weissfeld J. Doubling times and CT screen–detected lung cancers in the Pittsburgh Lung Screening Study. Am. J. Respir. Crit. Care Med. 2012 185 1 85 89 10.1164/rccm.201107‑1223OC 21997335
    [Google Scholar]
  6. Honda O. Johkoh T. Sekiguchi J. Tomiyama N. Mihara N. Sumikawa H. Inoue A. Yanagawa M. Daimon T. Okumura M. Nakamura H. Doubling time of lung cancer determined using three-dimensional volumetric software: Comparison of squamous cell carcinoma and adenocarcinoma. Lung Cancer 2009 66 2 211 217 10.1016/j.lungcan.2009.01.018 19250697
    [Google Scholar]
  7. Sabbula B.R. Gasalberti D.P. Anjum F. Squamous cell lung cancer. StatPearls StatPearls Publishing Treasure Island (FL) 2024
    [Google Scholar]
  8. Paik P.K. Pillai R.N. Lathan C.S. Velasco S.A. Papadimitrakopoulou V. New treatment options in advanced squamous cell lung cancer. Am. Soc. Clin. Oncol. Educ. Book 2019 39 e198 e206 10.1200/EDBK_237829 31099625
    [Google Scholar]
  9. Qu J. Wang L. Jiang M. Zhao D. Wang Y. Zhang F. Li J. Zhang X. A review about pembrolizumab in first-line treatment of advanced NSCLC: Focus on KEYNOTE studies. Cancer Manag. Res. 2020 12 6493 6509 10.2147/CMAR.S257188 32801888
    [Google Scholar]
  10. Doroshow D.B. Sanmamed M.F. Hastings K. Politi K. Rimm D.L. Chen L. Melero I. Schalper K.A. Herbst R.S. Immunotherapy in non–small cell lung cancer: Facts and hopes. Clin. Cancer Res. 2019 25 15 4592 4602 10.1158/1078‑0432.CCR‑18‑1538 30824587
    [Google Scholar]
  11. Reck M. Remon J. Hellmann M.D. First-line immunotherapy for non–small-cell lung cancer. J. Clin. Oncol. 2022 40 6 586 597 10.1200/JCO.21.01497 34985920
    [Google Scholar]
  12. Wang C. Qiao W. Jiang Y. Zhu M. Shao J. Wang T. Liu D. Li W. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis. J. Cell. Physiol. 2020 235 5 4913 4927 10.1002/jcp.29371 31693178
    [Google Scholar]
  13. Schoenfeld A.J. Hellmann M.D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 2020 37 4 443 455 10.1016/j.ccell.2020.03.017 32289269
    [Google Scholar]
  14. Lei T. Xu T. Zhang N. Zou X. Kong Z. Wei C. Wang Z. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis. Pharmacol. Res. 2023 188 106668 10.1016/j.phrs.2023.106668
    [Google Scholar]
  15. Wang G. Sun M. Jiang Y. Zhang T. Sun W. Wang H. Yin F. Wang Z. Sang W. Xu J. Mao M. Zuo D. Zhou Z. Wang C. Fu Z. Wang Z. Duan Z. Hua Y. Cai Z. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int. J. Cancer 2019 145 4 979 993 10.1002/ijc.32180 30719715
    [Google Scholar]
  16. Shen G. Zheng F. Ren D. Du F. Dong Q. Wang Z. Zhao F. Ahmad R. Zhao J. Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol. 2018 11 1 120 10.1186/s13045‑018‑0664‑7 30231931
    [Google Scholar]
  17. Zhou M. Chen X. Zhang H. Xia L. Tong X. Zou L. Hao R. Pan J. Zhao X. Chen D. Song Y. Qi Y. Tang L. Liu Z. Gao R. Shi Y. Yang Z. China National Medical Products Administration approval summary: Anlotinib for the treatment of advanced non‐small cell lung cancer after two lines of chemotherapy. Cancer Commun. (Lond.) 2019 39 1 1 10 10.1186/s40880‑019‑0383‑7 31221221
    [Google Scholar]
  18. Hsin Feng S. Yang S.T. The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. Diagn. Interv. Radiol. 2019 25 4 270 279 10.5152/dir.2019.18458 31295144
    [Google Scholar]
  19. Jett J.R. Schild S.E. Kesler K.A. Kalemkerian G.P. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2013 143 5 e400S e419S 10.1378/chest.12‑2363
    [Google Scholar]
  20. Veldhuijzen E. Walraven I. Belderbos J. Selecting a subset based on the patient-reported outcomes version of the common terminology criteria for adverse events for patient-reported symptom monitoring in lung cancer treatment: Mixed methods study. JMIR Cancer 2021 7 3 e26574 10.2196/26574 34519658
    [Google Scholar]
  21. Wang W. Shao L. Xu Y. Song Z. Lou G. Zhang Y. Chen M. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: A retrospective study. BMC Pulm. Med. 2022 22 1 179 10.1186/s12890‑022‑01981‑5 35524294
    [Google Scholar]
  22. Shi Y. Ji M. Jiang Y. Yin R. Wang Z. Li H. Wang S. He K. Ma Y. Wang Z. Lu J. Shi M. Shen B. Zhou G. Leong T.L. Wang X. Chen C. Feng J. A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world. Transl. Lung Cancer Res. 2022 11 6 1051 1068 10.21037/tlcr‑22‑350 35832459
    [Google Scholar]
  23. Yuan S. Peng L. Liu Y. Till B.G. Yan X. Zhang J. Zhu L. Wang H. Zhang S. Li H. Gao Q. Wang Z. Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients. Cancer Immunol. Immunother. 2023 72 2 437 448 10.1007/s00262‑022‑03259‑5 35931835
    [Google Scholar]
  24. Zhou F. Qiao M. Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell. Mol. Immunol. 2021 18 2 279 293 10.1038/s41423‑020‑00577‑5 33177696
    [Google Scholar]
  25. Brahmer J. Reckamp K.L. Baas P. Crinò L. Eberhardt W.E.E. Poddubskaya E. Antonia S. Pluzanski A. Vokes E.E. Holgado E. Waterhouse D. Ready N. Gainor J. Arén Frontera O. Havel L. Steins M. Garassino M.C. Aerts J.G. Domine M. Paz-Ares L. Reck M. Baudelet C. Harbison C.T. Lestini B. Spigel D.R. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N. Engl. J. Med. 2015 373 2 123 135 10.1056/NEJMoa1504627 26028407
    [Google Scholar]
  26. He L. Chen X. Ding L. Zhang X. Clinical efficacy of antianlotinib combined with immune checkpoint inhibitors in the treatment of advanced non-small-cell lung cancer and its effect on serum VEGF, CEA, and SCC-Ag. J. Oncol. 2022 2022 1 8 10.1155/2022/1530875 36276277
    [Google Scholar]
  27. Wang Y. Li L. Xu C. Nanoparticle albumin bound paclitaxel in the third-line treatment of recurrent small cell lung cancer in real-world practice: A single center experience. Technol. Cancer Res. Treat. 2021 20 10.1177/15330338211050775 34657492
    [Google Scholar]
  28. Ready N. Hellmann M.D. Awad M.M. Otterson G.A. Gutierrez M. Gainor J.F. Borghaei H. Jolivet J. Horn L. Mates M. Brahmer J. Rabinowitz I. Reddy P.S. Chesney J. Orcutt J. Spigel D.R. Reck M. O’Byrne K.J. Paz-Ares L. Hu W. Zerba K. Li X. Lestini B. Geese W.J. Szustakowski J.D. Green G. Chang H. Ramalingam S.S. First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J. Clin. Oncol. 2019 37 12 992 1000 10.1200/JCO.18.01042 30785829
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096299425240925073611
Loading
Clinical Efficacy and Safety of Anlotinib Combined with Immune 
Checkpoint Inhibitors in the Treatment of Advanced Squamous Cell Lung Cancer: A Retrospective Single-Center Study in China
Bentham Science Publishers ; https://doi.org/10.2174/0115680096299425240925073611
/content/journals/ccdt/10.2174/0115680096299425240925073611
/content/journals/ccdt/10.2174/0115680096299425240925073611
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: advanced squamous cell lung cancer ; Anlotinib ; immune checkpoint inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test